MINI LONG - NOVO-NORDISK B | Real-time Bid/Ask 08:26:22 01/07/2024 BST | ||
| 17.13 EUR / 17.14 EUR | -0.26% |
|
| Current month | +13.32% | ||
| 1 month | +13.47% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 28/06/24 | 17.18 | -0.75% |
| 27/06/24 | 17.31 | +0.06% |
| 26/06/24 | 17.3 | -2.20% |
| 25/06/24 | 17.69 | +5.17% |
| 24/06/24 | 16.82 | -0.65% |
Delayed Quote Börse Stuttgart
Last update June 28, 2024 at 05:26 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | MD2U1W |
| ISIN | DE000MD2U1W9 |
| Date issued | 21/03/2022 |
| Strike | 361.2 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 1.26 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 17.69 € |
|---|---|
| Lowest since issue | 1.16 € |
| Spread | 0.01 € |
| Spread % | 0.06% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,006
DKK
Average target price
949.7
DKK
Spread / Average Target
-5.56%
- Stock Market
- Certificates
- Certificat
